Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Gate Bioscience wants to tailor gates that stop problematic proteins at the source.
Login or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Besemer, J. et al. Nature 436, 290–293 (2005).
Garrison, J., Kunkel, E. J., Hegde, R. S. & Taunton, J. Nature 436, 285–289 (2005).
Rehan, S. et al. Nat. Chem. Biol. 19, 1054–1062 (2023).
Itskanov, S. et al. Nat. Chem. Biol. 19, 1063–1071 (2023).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marx, V. Editor’s pick: Gate Bioscience. Nat Biotechnol 42, 1763–1764 (2024). https://doi.org/10.1038/s41587-024-02483-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-024-02483-x
